Skip to content. Skip to navigation
Personal tools
  Members Area  

ANZCA

Sections
You are here: Home → Events → ANZCA Annual Scientific Meetings → 2008 ASM → Abstracts → C-reactive protein is not a marker of cognitive impairment in patients with cardiovascular disease
Navigation
News
24-08-2008
New drug
A new drug has just been approved for use in Australia. SITAGLIPTIN (Januvia) is an oral drug for type 2 Diabetes mellitus. It is a new class of drug, a dipeptidyl peptidase (DPP-4) inhibitor. Sitagliptin is an 'incretin enhancer' that increases the levels of active incretin by inhibiting their metabolism by DPP-4, thus prolonging their effect in stimulating insulin release and decreasing glucagon secretion.
More
24-08-2008
The latest ANZCA e-newsletter has been emailed
The latest edition of ANZCA’s e-newsletter has now been emailed to Fellows, trainees and ANZCA staff.
More
21-08-2008
Fellowship Affairs
The first meeting of the Fellowship Affairs Committee was held on Friday, 15 August 2008. Chaired by Dr Margaret Cowling, the Committee oversees all matters directly pertinent to Fellows, including CPD, annual scientific meetings, Regional CME and SIG events, communications and professional issues
More
20-08-2008
RFT for Australian Clinical Quality Registries pilot projects
The Australian Commission on Safety and Quality in Health Care is seeking tenders from relevant organisations to test and validate the draft 'Operating Principles and Technical Standards for Australian Clinical Quality Registries'.
More
20-08-2008
Electricity & greenhouse emissions
You might wonder whether turning off the lights when not required actually saves energy. Thanks to the efforts of College staff, we have saved a massive 15 per cent greenhouse gas emissions over the last six months compared to last year. A lot of this can be attributed to turning off lights and switching to energy efficient flourescent light globes. The impact has been significant.
More
More news…
 
Document Actions

C-reactive protein is not a marker of cognitive impairment in patients with cardiovascular disease

Brendan Silbert1, Lisbeth Evered1, David Scott1, Craig McCutcheon1, Konrad Jamrozik2

1Centre for Anaesthesia and Cognitive Function, Department of Anaesthesia, St Vincent’s Health, Melbourne, Australia
2School of Population Health and Clinical Practice (K.J.), University of Adelaide, Australia

Background: C-reactive protein (CRP) is recognised as a strong and independent risk factor for cardiovascular disease which may not only be a marker but also one of the participants of the inflammatory process associated with atherosclerosis. CRP has also been implicated as an independent risk factor for cognitive impairment in population studies.

Objectives: To investigate the association of CRP with cognition in patients presenting for elective coronary artery bypass graft (CABG) surgery.

Methods: Cognition was assessed in 264 patients using a standard battery of eight neuropsychological tests. The test battery consisted of the CERAD Auditory Verbal Learning test, Digit Symbol Substitution test, Trail Making test parts A and B, Controlled Oral Word Association Test (COWAT), Semantic Fluency test, and the Grooved Pegboard test (dominant and non-dominant hands). Patients were classified as having preoperative cognitive impairment by reference to a healthy control group or postoperative cognitive dysfunction by reference to baseline test scores.

Results: Preoperative cognitive impairment was present in 37.3% of patients and postoperative cognitive dysfunction present 18.3%, 12.1% and 13.6% of patients at one week, 3 months and 12 months postoperatively. On multivariable analysis CRP was not independently associated with cognition at any testing time but was strongly associated with age and left ventricular function.

Conclusion: Preoperative cognitive impairment and a postoperative cognitive dysfunction are present in a substantial proportion of patients undergoing CABG surgery but there is no independent association with baseline CRP levels. It is possible that cognitive impairment may result from the vascular disease rather than a direct association with CRP.